PAML and Axela partner for diseases preventable with vaccines
PAML is one of the leading medical reference laboratories in the United States. Axela specializes in protein analysis and multiplexed nucleic acid for clinical diagnostics.
As part of the agreement, the multiplex targets will be expanded beyond the program’s original serological assays, which measure a patient’s immunity level against measles, mumps, and rebella. PAML will test the products only within the U.S. as Azela markets its top analyzer and point-of-use formats to the entire world.
"Partnering with Axela reflects PAML's strong commitment to technological innovation and the expansion of our esoteric test menu,” PAML President and CEO Francisco R. Velazquez said. “Having access to rapid, sensitive and highly multiplexed assays will allow us to economically target emerging customer needs such as the recent focus on verifying proper immunization. As our menu expands, we will take advantage of the exquisite sensitivity of Axela's technology to enable testing from additional specimen types such as the dried blood spots used in our direct-to-consumer Cinch offering."
The collaboration will be mutually beneficial to PAML and Axela.
"We are excited to be working with one of the top reference labs in the country to implement our new technology,” Axela President and COO Paul Smith said. “We also share PAML's vision of making testing more accessible to the community by driving down the cost and complexity. Our platforms are capable of delivering a menu of both nucleic acid and protein tests economically, whether in a high throughput reference lab or a single point of use determination. Partnering with PAML, an organization that is highly focused on its' customers, will ensure these new tests are designed to provide the best possible client and patient value."